drugset / Trial / NCT04322227

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

NCT04322227

Phase 1 Terminated 6 enrolled H. Lundbeck A/S
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

Timeline

Start
2020-01-23
Primary completion
2020-05-30
Completion
2020-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Foliglurax Small molecule 10 mg Oral
Subject Foliglurax Small molecule 30 mg Oral

Indications